Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 98

Sort by

Sort Order Select

Journal Articles

Deletion 17p: a matter of size and number?

Sonja Zweegman, Niels W. C. J. van de Donk

Blood (2021) 137 (9): 1135–1136.

https://doi.org/10.1182/blood.2020009102

Published: 2021

Journal Articles

Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial

Jean Roy, MD, Tony Panzarella, M.Sc., P.Stat, Stephen Couban, MDBSc, Félix Couture, MD FRCPC, Gerald M. Devins, PhD, Mohamed Elemary, MD, Stephen Ronan Foley, MD FRCPC, Genevieve Gallagher, MD, John Kuruvilla, MD, Stephanie J. Lee, MD MPH, John Moore, MDFRACP,FRCPA, Thomas J Nevill, MD, Gizelle Popradi, MD FRCP, Kirk R. Schultz, MD, David Szwajcer, MD FRCPC, Cynthia L Toze, MD FRCPC, Irwin Walker, MBBS, FRCPC

Blood (2019) 134 (Supplement_1): 875.

https://doi.org/10.1182/blood-2019-123275

Published: 2019

Journal Articles

Gck Kinase Activity Is Critical for RAS Mutated Myeloma - a Potential Treatment Approach for Targeting Specific Mutations

Shirong Li, PhD, Jing Fu, PhD, Xiaoming Xu, PhD, Shixian Deng, PhD, Markus Y Mapara, MD PhD, Christophe Marcireau, Suzanne Lentzsch, MD PhD

Blood (2019) 134 (Supplement_1): 1813.

https://doi.org/10.1182/blood-2019-129531

Published: 2019

Journal Articles

ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

Blood (2019) 134 (Supplement_1): 31.

https://doi.org/10.1182/blood-2019-128404

Published: 2019

Journal Articles

Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors

Denis Claude Roy, MD, Irwin Walker, MBBS, FRCPC, Johan A. Maertens, MD PhD, Philippe Lewalle, Eduardo Olavarria, MD PhD, Yves Beguin, MD PhD, Dominik Selleslag, MD, Eva Maria Wagner, MD, Halvard Bönig, Gerard Bos, MD PhD, Stephan Mielke, MD

Blood (2019) 134 (Supplement_1): 592.

https://doi.org/10.1182/blood-2019-128344

Published: 2019

Journal Articles

The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma

Carolina D. Schinke, MD, Pingping Qu, Shmuel Yaccoby, PhD, Valeriy V Lyzogubov, MD PhD, Veronica MacLeod, Eileen M Boyle, Randal Shelton, Wen Ling, PhD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD, Bart Barlogie, MD PhD, Frits van Rhee, MD PhD, Brian A Walker, PhD

Blood (2019) 134 (Supplement_1): 508.

https://doi.org/10.1182/blood-2019-130595

Published: 2019

Journal Articles

Large-Scale Analysis of Relapsed/Refractory Multiple Myeloma Genome Reveals Increased Prevalence of High-Risk Molecular Features and Oncogenic Drivers

Fadi Towfic, PhD, Naser Ansari-Pour, PhD, Maria Ortiz, Sarah Gooding, MD PhD, Dan Rozelle, PhD, Victoria Zadorozhny, Konstantinos Mavrommatis, PhD, Sneh Lata, PhD, Nicholas Stong, PhD, Sitharthan Kamalakaran, PhD, Kao-Tai Tsai, Erin Flynt, Anjan Thakurta

Blood (2019) 134 (Supplement_1): 365.

https://doi.org/10.1182/blood-2019-124939

Published: 2019

Journal Articles

Gene Expression and Genomic Markers Identify a Subpopulation of Poor Prognosis t(4;14) Patients in Newly Diagnosed Multiple Myeloma

Maria Ortiz, Fadi Towfic, PhD, Erin Flynt, Nicholas Stong, PhD, Sneh Lata, PhD, Dharanya Sampath, Dan Rozelle, PhD, Matthew Trotter, PhD, Jill Corre, PharmD, PhD, Hervé Avet-Loiseau, MD PhD, Anjan Thakurta

Blood (2019) 134 (Supplement_1): 366.

https://doi.org/10.1182/blood-2019-128907

Published: 2019

Journal Articles

Calpain-1 Contributes to Pain and Organ Damage in Sickle Cell Disease

Stacy B Kiven, BS, Jianxun Lei, PhD, Varun Sagi, BS, Huy Tran, BS, Ying Wang, PhD, Piyusha P Pagare, PhD, Jennifer O Nwankwo, PhD, Nils Lambrecht, MD PhD, Kalpna Gupta, PhD

Blood (2019) 134 (Supplement_1): 76.

https://doi.org/10.1182/blood-2019-127761

Published: 2019

Journal Articles

Crowdsourced High-Risk Classifiers for Multiple Myeloma Patients Commonly Identify PHF19 As a Robust Progression Biomarker

Blood (2019) 134 (Supplement_1): 4370.

https://doi.org/10.1182/blood-2019-127362

Published: 2019

Journal Articles

The Spectrum of Exomic Mutation in Elderly Myeloma Differs Substantially from Patients at Younger Ages Consistent with a Different Evolutionary Trajectory to Full Blown Disease Based on Age of Onset

Louis Williams, MD MBA, Eileen M Boyle, MD MSc, Faith E. Davies, MD, Brian A Walker, PhD, Cody Ashby, PhD, Michael A Bauer, PhD, Christopher P. Wardell, PhD MSc, BSc, Erin Flynt, Anjan Thakurta, Gareth Morgan, MD PhD

Blood (2019) 134 (Supplement_1): 4346.

https://doi.org/10.1182/blood-2019-130079

Published: 2019

Journal Articles

Chromoplexy and Chromothripsis Are Important Prognostically in Myeloma and Deregulate Gene Function By a Range of Mechanisms

Cody Ashby, PhD, Eileen M Boyle, MD MSc, Brian A Walker, PhD, Michael A Bauer, PhD, Katie Rose Ryan, PhD, Judith Dent, Anjan Thakurta, Erin Flynt, Faith E. Davies, MD, Gareth Morgan, MD PhD

Blood (2019) 134 (Supplement_1): 3767.

https://doi.org/10.1182/blood-2019-130335

Published: 2019

Journal Articles

Small Molecule-Induced, Selective STAT3 Degradation Leads to Anti-Tumor Activity in STAT3-Dependent Heme Malignancies

Fred Csibi, Nan Ji, PhD, Bin Yang, Karen Yuan, Michele Mayo, Haojing Rong, PhD, Scott Rusin, Kirti Sharma, Christine Loh, PhD, Henry Li, PhD, Sharon Townson, Jesse Chen, PhD, Hari Kamadurai, PhD, Duncan Walker, PhD, Jared Gollob, PhD MD, Nello Mainolfi, PhD

Blood (2019) 134 (Supplement_1): 3803.

https://doi.org/10.1182/blood-2019-128981

Published: 2019

Journal Articles

Mutant KRAS Enhances Stress Granules and Resistance to Proteasome Inhibition Via 15-d-PGJ2 in Multiple Myeloma

Ya-Wei Qiang, MD PhD, Shiqiao Ye, PhD BSc, MSc, Yu Chen, Joshua Epstein, DSc, Faith E. Davies, MD, Gareth Morgan, MD PhD, Brian A Walker, PhD, Frits van Rhee, MD PhD

Blood (2019) 134 (Supplement_1): 4383.

https://doi.org/10.1182/blood-2019-130493

Published: 2019

Journal Articles

The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells

Syed J. Mehdi, PhD, Sarah K Johnson, PhD, Tarun K. Garg, PhD, Cody Ashby, PhD, Maurizio Zangari, MD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Joshua Epstein, DSc, Brian A Walker, PhD, Frits van Rhee, MD PhD, Shmuel Yaccoby, PhD

Blood (2019) 134 (Supplement_1): 4412.

https://doi.org/10.1182/blood-2019-127382

Published: 2019

Journal Articles

Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients

J Christine Ye, MDMSc, Liying Chen, Jason Chen, MD, Brian Parkin, Avery Polk, Malathi Kandarpa, PhD, Craig E. Cole, MD, Erica L. Campagnaro, MD, Dan Robinson, PhD, Yi-Mi Wu, Moshe Talpaz, MD, Jennifer Yesil, Daniel Auclair, P. Leif Bergsagel, MD, Arul Chinnaiyan, MD, Veerabhadran Baladandayuthapani

Blood (2019) 134 (Supplement_1): 4360.

https://doi.org/10.1182/blood-2019-124135

Published: 2019

Journal Articles

EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab

Frits van Rhee, MD PhD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Jeffery R. Sawyer, Adam Rosenthal, MS, Doug Steward, Phil Farmer, Robert Smith, Milan Bimali, PhD, Mariam M. Boota, MD, Clyde Bailey, Brian A Walker, PhD, Antje Hoering, PhD, Gareth Morgan, MD PhD, Maurizio Zangari, MD, Faith E. Davies, MD

Blood (2019) 134 (Supplement_1): 4569.

https://doi.org/10.1182/blood-2019-131887

Published: 2019

Journal Articles

Prognostic Molecular Stratification in Relapsed/Refractory Multiple Myeloma - Results of the Pomalidomide Mukseven (NCT02406222) Biomarker Trial

James Croft, MBBS, BSc, Andrew Hall, Amy L Sherborne, PhD, Katrina Walker, Sidra Ellis, Kim Sharp, Amy Price, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Louise Flanagan, PhD, Mamta Garg, MD FRCP, FRCPath, Suzana Couto, Maria Wang, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, William E Pierceall, PhD, Anjan Thakurta, Gordon Cook, Sarah R Brown, PhD MSc, BSc, Martin F. Kaiser

Blood (2019) 134 (Supplement_1): 4327.

https://doi.org/10.1182/blood-2019-123640

Published: 2019

Journal Articles

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial

Blood (2019) 134 (Supplement_1): 499.

https://doi.org/10.1182/blood-2019-125394

Published: 2019

Journal Articles

Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Myeloma

Eileen M Boyle, MD MSc, Faith E. Davies, MD, Shayu Deshpande, Ruslana G. Tytarenko, MS, Cody Ashby, PhD, Yan Wang, Christopher P. Wardell, PhD MSc, BSc, Michael A Bauer, PhD, Sarah K Johnson, PhD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Louis Williams, MD MBA, Thierry Facon, MD, Charles Dumontet, Bart Barlogie, MD PhD, Gareth Morgan, MDPhDFRCP, Brian A Walker, PhD

Blood (2019) 134 (Supplement_1): 4333.

https://doi.org/10.1182/blood-2019-126679

Published: 2019

NARROW

Deletion 17p: a matter of size and number?

Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial

Gck Kinase Activity Is Critical for RAS Mutated Myeloma - a Potential Treatment Approach for Targeting Specific Mutations

ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors

The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma

Large-Scale Analysis of Relapsed/Refractory Multiple Myeloma Genome Reveals Increased Prevalence of High-Risk Molecular Features and Oncogenic Drivers

Gene Expression and Genomic Markers Identify a Subpopulation of Poor Prognosis t(4;14) Patients in Newly Diagnosed Multiple Myeloma

Calpain-1 Contributes to Pain and Organ Damage in Sickle Cell Disease

Crowdsourced High-Risk Classifiers for Multiple Myeloma Patients Commonly Identify PHF19 As a Robust Progression Biomarker

The Spectrum of Exomic Mutation in Elderly Myeloma Differs Substantially from Patients at Younger Ages Consistent with a Different Evolutionary Trajectory to Full Blown Disease Based on Age of Onset

Chromoplexy and Chromothripsis Are Important Prognostically in Myeloma and Deregulate Gene Function By a Range of Mechanisms

Small Molecule-Induced, Selective STAT3 Degradation Leads to Anti-Tumor Activity in STAT3-Dependent Heme Malignancies

Mutant KRAS Enhances Stress Granules and Resistance to Proteasome Inhibition Via 15-d-PGJ2 in Multiple Myeloma

The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells

Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients

EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab

Prognostic Molecular Stratification in Relapsed/Refractory Multiple Myeloma - Results of the Pomalidomide Mukseven (NCT02406222) Biomarker Trial

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial

Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only